Q3 2024 Earnings Call Transcript November 5, 2024 Apellis Pharmaceuticals, Inc. misses on earnings expectations. Reported EPS is $-0.46 EPS, expectations were $-0.32. Operator: Good morning, ladies ...

Apellis Pharmaceuticals, Inc. APLS incurred third-quarter 2024 loss of 46 cents per share, wider than the Zacks Consensus Estimate of a loss of 32 cents. The company had incurred a loss of $1.17 per ...

LumiThera's Valeda Light Delivery System generates light at different wavelengths to stimulate and improve the function of retinal mitochondria. The photobiomodulation (PBM) system is the first ...

Analyst Yigal Nochomovitz from Citi assigned a Buy rating on Apellis Pharmaceuticals (APLS – Research Report) and decreased the price ...

Despite witnessing modest growth in demand over the past three months, Apellis Pharmaceuticals’ complement inhibitor for ...

Generated $196.8 million in 3Q 2024 revenues, including $176.6 million in U.S. net product salesGrew SYFOVRE® (pegcetacoplan injection) demand by ...

If your vision is blurry or fuzzy, or if you notice that straight lines appear curved or wavy, you may have age-related macular degeneration (AMD). This eye disease is more common in older adults ...

Throughout the 26-week randomized, controlled treatment period, pegcetacoplan demonstrated favorable safety and tolerability. It also showed high compliance rates, consistent with its known profile.

Plus, there's a chance the active ingredient in Syfovre, called pegcetacoplan, could earn approval as a treatment for patients with another pair of rare diseases: C3 glomerulopathy (C3G ...

Detailed price information for Apellis Pharmaceuticals Inc (APLS-Q) from The Globe and Mail including charting and trades.